scholarly journals Aberrant DNA Methylation of SEPT9 and SDC2 in Stool Specimens as an Integrated Biomarker for Colorectal Cancer Early Detection

2020 ◽  
Vol 11 ◽  
Author(s):  
Guodong Zhao ◽  
Xiaoyu Liu ◽  
Yi Liu ◽  
Hui Li ◽  
Yong Ma ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
Early Detection ◽  
Cancer Early Detection ◽  
Stool Specimens ◽  
Aberrant Dna Methylation

scholarly journals LSD1 and aberrant DNA methylation mediate persistence of enteroendocrine progenitors that support BRAF mutant colorectal cancer

2021 ◽  
pp. canres.3562.2020
Author(s):  
Samuel A. Miller ◽  
Robert A. Policastro ◽  
Shruthi Sriramkumar ◽  
Tim Lai ◽  
Thomas D. Huntington ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
Aberrant Dna Methylation ◽  
Braf Mutant

scholarly journals DNA Methylation in Colorectal cancer—Impact on Screening and Therapy Monitoring Modalities?

2007 ◽  
Vol 23 (1-2) ◽  
pp. 51-71 ◽  
Author(s):  
Marion Zitt ◽  
Matthias Zitt ◽  
Hannes M. Müller
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
Early Detection ◽  
Therapy Monitoring ◽  
Specific Treatment ◽  
Genetic Alterations ◽  
Neoplastic Disease ◽  
Aberrant Methylation ◽  
Colon Polyps ◽  
Histological Progression

Colorectal cancer (CRC) is a common malignancy. It arises from benign neoplasms and evolves into adenocarcinomas through a stepwise histological progression sequence, proceeding from either adenomas or hyperplastic polyps/serrated adenomas. Genetic alterations have been associated with specific steps in this adenoma-carcinoma sequence and are believed to drive the histological progression of CRC. Recently, epigenetic alterations (especially DNA methylation) have been shown to occur in colon polyps and CRC. The aberrant methylation of genes appears to act together with genetic alterations to drive the initiation and progression of colon polyps to CRC.DNA methylation changes have been recognized as one of the most common molecular alterations in human tumors, including CRC. Because of the ubiquity of DNA methylation changes and the ability to detect methylated DNA in several body fluids (blood, stool), this specifically altered DNA may serve, on the one hand, as a possible new screening marker for CRC and, on the other hand, as a tool for therapy monitoring in patients having had neoplastic disease of the colorectum.As many CRC patients present with advanced disease, early detection seems to be one of the most important approaches to reduce mortality. Therefore, an effective screening test would have substantial clinical benefits. Furthermore, early detection of progression of disease in patients having had CRC permits immediate commencement of specific treatment regimens (e.g. curative resection of liver and lung metastases) and probably longer survival and better quality of life.

Aberrant DNA methylation of acute myeloid leukemia and colorectal cancer in a Chinese pedigree with a MLL3 germline mutation

Tumor Biology ◽  
2016 ◽  
Vol 37 (9) ◽  
pp. 12609-12618 ◽  
Author(s):  
Fuhua Yang ◽  
Qiang Gong ◽  
Wentao Shi ◽  
Yunding Zou ◽  
Jingmin Shi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
Acute Myeloid Leukemia ◽  
Germline Mutation ◽  
Myeloid Leukemia ◽  
Aberrant Dna Methylation ◽  
Acute Myeloid

scholarly journals Aberrant DNA Methylation in Hereditary Nonpolyposis Colorectal Cancer Without Mismatch Repair Deficiency

2010 ◽  
Vol 138 (5) ◽  
pp. 1854-1862.e1 ◽  
Author(s):  
Ajay Goel ◽  
Rosa M. Xicola ◽  
Thuy–Phuong Nguyen ◽  
Brian J. Doyle ◽  
Vanessa R. Sohn ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
Mismatch Repair ◽  
Hereditary Nonpolyposis Colorectal Cancer ◽  
Mismatch Repair Deficiency ◽  
Repair Deficiency ◽  
Hereditary Nonpolyposis ◽  
Aberrant Dna Methylation
Sign in / Sign up

Export Citation Format

Share Document